$IVF earnings report

INVO Fertility Q3 2026: total revenue of $2,222,656, up 26%; net loss narrows to $(2,149,920) from $(3,395,598). AlphAI read INVO Fertility's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readIVF · Q3 2026 · ended 2026-09-30

INVO Fertility Q3 2026: total revenue of $2,222,656, up 26%; net loss narrows to $(2,149,920) from $(3,395,598)

→Mixed quarter

Revenue grew 26% and clinic revenue grew 28%, and clinic-level Adjusted EBITDA rose to $292,114 from $243,120. Against that, consolidated Adjusted EBITDA was $(961,704) versus $(947,568), operating expenses rose, and the nine-month results carry a $(4,353,222) loss on change in fair value of derivatives against a $1,626,594 gain a year earlier.

Revenue
$2,222,656
26% y/y
Fertility Clinic Services, Q3 2026 clinic revenue
$2,207,587
28% y/y
EPS · GAAP
$(2.44)

Key metrics

as reported
MetricValueq/qy/y
Total revenue, Q3 2026GAAP$2,222,656–26%
Clinic revenue, Q3 2026GAAP$2,207,587–28%
Product revenue, Q3 2026GAAP$15,069––
Total revenue, nine months 2026GAAP$6,413,366––
Clinic revenue, nine months 2026GAAP$6,357,605––
Product revenue, nine months 2026GAAP$55,761––
Cost of services, Q3 2026GAAP$1,436,870––
Cost of services, nine months 2026GAAP$4,071,782––
Cost of goods sold, Q3 2026GAAP$14,144––
Cost of goods sold, nine months 2026GAAP$79,443––
Selling, general and administrative expenses, Q3 2026GAAP$2,071,438––
Selling, general and administrative expenses, nine months 2026GAAP$6,154,287––
Impairment loss, nine months 2026GAAP-––
Depreciation and amortization, Q3 2026GAAP$177,564––
Depreciation and amortization, nine months 2026GAAP$465,835––
Total operating expenses, Q3 2026GAAP$3,700,016––
Total operating expenses, nine months 2026GAAP$10,771,347––
Loss from operations, Q3 2026GAAP$(1,477,360)––
Loss from operations, nine months 2026GAAP$(4,357,981)––
Gain (loss) on change in fair value of derivatives, Q3 2026GAAP$(562,997)––
Gain (loss) on change in fair value of derivatives, nine months 2026GAAP$(4,353,222)––
Gain on remeasurement, nine months 2026GAAP$2,452,032––
Loss on debt extinguishment, Q3 2026GAAP-––
Loss on debt extinguishment, nine months 2026GAAP$(172,621)––
Interest income, Q3 2026GAAP$74,735––
Interest income, nine months 2026GAAP$214,249––
Interest expense, Q3 2026GAAP$(154,768)––
Interest expense, nine months 2026GAAP$(512,318)––
Total other income (expense), Q3 2026GAAP$(643,030)––
Total other income (expense), nine months 2026GAAP$(2,356,866)––
Net loss from continuing operations before income taxes, Q3 2026GAAP$(2,120,390)––
Net loss from continuing operations before income taxes, nine months 2026GAAP$(6,714,847)––
Provision for income taxes, Q3 2026GAAP$29,530––
Provision for income taxes, nine months 2026GAAP$85,684––
Net loss from continuing operations, Q3 2026GAAP$(2,149,920)––
Net loss from continuing operations, nine months 2026GAAP$(6,800,531)––
Net loss, Q3 2026GAAP$(2,149,920)––
Net loss, nine months 2026GAAP$(6,800,531)––
Net loss from continuing operations per share, basic and diluted, Q3 2026GAAP$(2.44)––
Net loss from continuing operations per share, basic and diluted, nine months 2026GAAP$(11.20)––
Net loss per common share, basic and diluted, nine months 2026GAAP$(11.20)––
Consolidated Adjusted EBITDA, Q3 2026non-GAAP$(961,704)––
Clinic-Level Adjusted EBITDA, Q3 2026non-GAAP$292,114––
Cash, September 30, 2026GAAP$3,695,770––
Total assets, September 30, 2026GAAP$25,500,200––
Total stockholders' equity, September 30, 2026GAAP$18,005,253––

Segments

SegmentRevenueq/qy/y
Fertility Clinic Services, Q3 2026 clinic revenueCompany explanation: higher revenue in Wisconsin and Atlanta and the addition of the Indiana and Birmingham clinics. Clinic revenue accounted for approximately $485,000 of year-over-year growth. Segment operating expenses were $2,144,678 (prior year $1,592,534), segment profit was $62,909 (prior year $129,689), and Clinic-Level Adjusted EBITDA was $292,114 (prior year $243,120), a non-GAAP measure.$2,207,587–28%
Product revenue, Q3 2026Company explanation: the decrease, from $34,871 in the prior-year quarter, partially reflects the elimination of sales to the Indiana and Birmingham clinics, which are now consolidated subsidiaries and treated as intercompany transactions.$15,069––

Capital returns

  • The release reports no share repurchases or dividends for the period.
  • In June 2026 INVO acquired the remaining 50% interest in its Birmingham clinic for an agreed purchase price of $175,001 payable to the sellers.
  • The release refers to a payment for the Wisconsin acquisition, but the amount is not printed in the document.
  • As of November 13, 2026 the Company had 1,192,860 shares of common stock outstanding.

What drove it

  • Company explanation: revenue grew at the Wisconsin and Atlanta clinics, and management believes Wisconsin's entry into the Progyny network in the first quarter contributed by expanding access for patients with Progyny coverage.
  • Company explanation: the Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each contributed a full quarter of revenue.
  • Company explanation: the planned Birmingham transition reduced the quarter's clinic-level contribution by approximately $193,000 (printed as $192,932 in the segment table) due to anticipated revenue disruption and increased costs of bringing in a new physician.
  • Company explanation: the net loss narrowed to approximately $2.1 million from approximately $3.4 million, and loss from operations improved to approximately $1.5 million from $1.6 million.
  • Company explanation: the cost of services increase reflects the cost of providing care across the expanded clinic network.

Concerns

  • Consolidated Adjusted EBITDA was $(961,704) versus $(947,568) in the prior-year quarter. The company states this measure includes the cost of operating the public company and supporting the clinic network.
  • Loss on change in fair value of derivatives was $(562,997) in Q3 2026 against $(33,566) a year earlier. For nine months it was $(4,353,222) against a $1,626,594 gain a year earlier.
  • Total operating expenses rose to $3,700,016 from $3,392,578, and cost of services rose to $1,436,870 from $1,121,174, while SG&A was $2,071,438 against $2,128,088.
  • Clinic-Level Adjusted EBITDA was reduced by the approximately $193,000 Birmingham transition, which the company describes as planned.
  • Interest expense fell to $(154,768) from $(322,765), but the release does not state a cause for the change beyond the balance sheet discussion.

What to watch

  • Clinic-Level Adjusted EBITDA after the Birmingham physician ramp, which the company says reduced Q3 contribution by approximately $193,000.
  • Derivative fair value movements, given the $745,288 derivative liability at September 30, 2026 and the nine-month loss of $(4,353,222).
  • Consolidated Adjusted EBITDA and the level of corporate and public company costs relative to clinic earnings.
  • Acquisition pipeline: management says it sees increased acquisition opportunities following ASRM attendance in October 2026.
  • Balance sheet: current liabilities fell to $4,457,529 from $10,331,629, with the company citing the Wisconsin acquisition payment.
  • Q3 2026 webcast on November 16, 2026 at 11:00 a.m. Eastern Time.

Balance sheet and cash flow

  • Cash: $3,695,770 at September 30, 2026 versus $2,077,842 at December 31, 2025. The release describes cash as approximately $3.7 million, or approximately $3.10 per share.
  • Total current liabilities: $4,457,529 at September 30, 2026 versus $10,331,629 at December 31, 2025.
  • Total assets: $25,500,200 at September 30, 2026 versus $20,220,124 at December 31, 2025.
  • Total liabilities: $7,494,947 at September 30, 2026 versus $12,995,903 at December 31, 2025.
  • Total stockholders' equity: $18,005,253 at September 30, 2026 versus $7,224,221 at December 31, 2025, or $15.09 per share as stated in the release.
  • Notes payable, current portion, net: $577,108 at September 30, 2026 versus $394,664 at December 31, 2025.
  • Notes payable, net of current portion: $362,445 at September 30, 2026 versus $744,725 at December 31, 2025.
  • Convertible note payable, related party, net: $17,882 at September 30, 2026 versus $880,000 at December 31, 2025.
  • Derivative liability: $745,288 at September 30, 2026; no such line is printed at December 31, 2025.
  • Additional payments for acquisitions, current portion: $998,000 at September 30, 2026 versus $3,925,000 at December 31, 2025.
  • Warrant liability: nil at September 30, 2026 versus $1,881,078 at December 31, 2025.
  • Operating and free cash flow are not reported in the document. No cash flow statement is included.

Analysis

INVO Fertility reported third quarter 2026 total revenue of $2,222,656, up 26% from $1,757,094, and clinic revenue of $2,207,587, up 28% from $1,722,223. The company attributes this to growth at its Wisconsin and Atlanta clinics, the Wisconsin Progyny network entry, and full-quarter contributions from the Indiana and Birmingham acquisitions. Product revenue fell to $15,069 from $34,871, which the company partly ties to eliminating sales to the two acquired clinics now treated as intercompany. For the nine months, total revenue was $6,413,366 against $5,257,933, and clinic revenue was $6,357,605 against $5,175,870.

Cost lines rose faster than the top line in the detail provided. Cost of services was $1,436,870 against $1,121,174, and cost of goods sold was $14,144 against $6,575. SG&A was broadly flat at $2,071,438 against $2,128,088. Total operating expenses were $3,700,016 against $3,392,578, and loss from operations narrowed to $(1,477,360) from $(1,635,484). Net loss from continuing operations narrowed to $(2,149,920) from $(3,395,598), or $(2.44) per share on a GAAP basis, though the improvement at the net line is driven largely by lower loss on debt extinguishment and interest expense in the comparison, not by operating gains alone.

The non-GAAP picture is more mixed. Clinic-Level Adjusted EBITDA was $292,114 against $243,120, and the company states that the clinic network was positive for a seventh consecutive quarter. The company also says the planned Birmingham transition reduced this contribution by approximately $193,000. Consolidated Adjusted EBITDA, which includes public company and corporate costs, was $(961,704) against $(947,568), essentially unchanged in loss terms.

Below the operating line, derivative fair value changes dominate the nine-month comparison. The company reports a $(4,353,222) loss on change in fair value of derivatives for nine months 2026, against a $1,626,594 gain a year earlier, and a $2,452,032 gain on remeasurement. These items make the reported net loss difficult to read as a run-rate measure, and the release does not provide a further breakdown.

The balance sheet improved relative to December 31, 2025 on the figures printed. Cash rose to $3,695,770 from $2,077,842, current liabilities fell to $4,457,529 from $10,331,629, and stockholders' equity rose to $18,005,253 from $7,224,221. The largest drop is in the current liability for acquisition payments, which fell to $998,000 from $3,925,000 and in the warrant liability, which is no longer printed. Against this, a derivative liability of $745,288 appears at September 30, 2026. The release provides no guidance, no prior-quarter comparison and no cash flow statement, so the quarter cannot be read against a stated outlook or sequential trend from this filing alone.

Management, verbatim

Revenue grew again this quarter, and our clinics continued to generate positive Adjusted EBITDA before corporate expenses.

Steve Shum, Chief Executive Officer, INVO Fertility

We continue to see increased opportunities for acquisitions, which remain a key component to our growth objectives, as independent fertility practices look for ways to serve more patients while preserving the local relationships that patients and physicians value.

Steve Shum, Chief Executive Officer, INVO Fertility

Not in the filing

stated, not guessed
  • No forward guidance for revenue, margins, operating expenses or tax rate is provided in the filing.
  • No prior-quarter (Q2 2026) figures are printed, so all qoq_change and prior_quarter fields are null.
  • Year-over-year percentage changes are printed only for total revenue (26%) and clinic revenue (28%); all other yoy_change fields are null.
  • Gross margin is not printed and is not calculated.
  • No cash flow statement is included; operating cash flow, investing cash flow and free cash flow are not reported.
  • Amount of the Wisconsin acquisition payment referenced in the release is not printed.
  • Consensus estimates, analyst expectations and share price reaction are not in the document.
  • Consolidated Adjusted EBITDA percentage change is not printed.
  • Prior-year comparatives for the balance sheet are shown only at December 31, 2025, not for the same quarter a year earlier.
  • Segment data is taken from Note 15 of the 10-Q referenced in the release; the note itself is not included in this filing text.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about IVF earnings dates

When is INVO Fertility's next earnings date?
AlphAI has no date for IVF yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.